Olodaterol HCl
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329649

CAS#: 869477-96-3 (HCl)

Description: Olodaterol, also known as BI 1744, is a long acting beta-adrenoceptor agonist used as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD), manufactured by Boehringer-Ingelheim. Olodaterol was approved by FDA in 2014 for the treatment of chronic obstructive pulmonary disease.


Price and Availability

Size
Price

10mg
USD 250
500mg
USD 2650
Size
Price

25mg
USD 450
1g
USD 3850
Size
Price

100mg
USD 1450
2g
USD 5650

Olodaterol HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329649
Name: Olodaterol HCl
CAS#: 869477-96-3 (HCl)
Chemical Formula: C21H27ClN2O5
Exact Mass:
Molecular Weight: 422.906
Elemental Analysis: C, 59.64; H, 6.44; Cl, 8.38; N, 6.62; O, 18.92


Related CAS #: 868049-49-4 (free base)   869477-96-3 (HCl)    

Synonym: Olodaterol hydrochloride; Olodaterol HCl; BI-1744; BI 1744; BI1744; Olodaterol; Striverdi

IUPAC/Chemical Name: (R)-6-hydroxy-8-(1-hydroxy-2-((1-(4-methoxyphenyl)-2-methylpropan-2-yl)amino)ethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride

InChi Key: KCEHVJZZIGJAAW-FERBBOLQSA-N

InChi Code: InChI=1S/C21H26N2O5.ClH/c1-21(2,10-13-4-6-15(27-3)7-5-13)22-11-18(25)16-8-14(24)9-17-20(16)28-12-19(26)23-17;/h4-9,18,22,24-25H,10-12H2,1-3H3,(H,23,26);1H/t18-;/m0./s1

SMILES Code: O=C1NC2=CC(O)=CC([C@@H](O)CNC(C)(C)CC3=CC=C(OC)C=C3)=C2OC1.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, Xue W, Maltais F. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. Eur Respir J. 2017 Apr 19;49(4). pii: 1601348. doi: 10.1183/13993003.01348-2016. Print 2017 Apr. PubMed PMID: 28424359.

2: Cataldo D. [Spiolto Respimat® : tiotropium-olodaterol fixed combination for therapy of chronic obstructive pulmonary disease (COPD)]. Rev Med Liege. 2016 Jun;71(6):308-313. Review. French. PubMed PMID: 28383865.

3: Ichinose M, Kato M, Takizawa A, Sakamoto W, Grönke L, Tetzlaff K, Fukuchi Y. Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease. Respir Investig. 2017 Mar;55(2):121-129. doi: 10.1016/j.resinv.2016.09.004. Epub 2016 Dec 22. PubMed PMID: 28274527.

4: Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:367-381. doi: 10.2147/COPD.S119908. eCollection 2017. PubMed PMID: 28176892; PubMed Central PMCID: PMC5261557.

5: Ferguson GT, Karpel J, Bennett N, Clerisme-Beaty E, Grönke L, Voß F, Buhl R. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017 Dec;27(1):7. doi: 10.1038/s41533-016-0002-x. Epub 2017 Feb 2. PubMed PMID: 28154373.

6: Koblížek V, Svoboda M. [Current position of new fixed-dose combination of tiotropium and olodaterol - its role in the treatment of chronic obstructive pulmonary disease in the Czech Republic]. Vnitr Lek. 2016 Winter;62(12):1011-1020. Czech. PubMed PMID: 28139131.

7: Płusa T. [New bronchodilation treatment options for patients with COPD]. Pol Merkur Lekarski. 2017 Jan 23;42(247):5-12. Polish. PubMed PMID: 28134225.

8: Price D, Østrem A, Thomas M, Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review. Int J Chron Obstruct Pulmon Dis. 2016 Dec 30;12:141-168. doi: 10.2147/COPD.S116719. eCollection 2017. Review. PubMed PMID: 28115839; PubMed Central PMCID: PMC5221557.

9: An update on LAMA/LABA combinations for COPD. Drug Ther Bull. 2017 Jan;55(1):2-5. doi: 10.1136/dtb.2017.1.0451. Epub 2017 Jan 5. PubMed PMID: 28057707.

10: Derom E, Brusselle GG, Joos GF. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD. Int J Chron Obstruct Pulmon Dis. 2016 Dec 13;11:3163-3177. doi: 10.2147/COPD.S92840. eCollection 2016. Review. PubMed PMID: 28008243; PubMed Central PMCID: PMC5167492.

11: Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2017 Jan;122:58-66. doi: 10.1016/j.rmed.2016.11.011. Epub 2016 Nov 14. PubMed PMID: 27993292.

12: Lee HW, Kim HJ, Lee CH. The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 Dec 13. doi: 10.1111/bcp.13210. [Epub ahead of print] PubMed PMID: 27957746.

13: Tamura T, Satoh H. Superiority of tiotropium plus olodaterol in comparison with salmeterol plus fluticasone. Int J Chron Obstruct Pulmon Dis. 2016 Nov 23;11:2909-2911. eCollection 2016. PubMed PMID: 27920517; PubMed Central PMCID: PMC5125986.

14: Tebboth A, Ternouth A, Gonzalez-Rojas N. UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD. Clinicoecon Outcomes Res. 2016 Nov 7;8:667-674. eCollection 2016. PubMed PMID: 27853383; PubMed Central PMCID: PMC5106216.

15: Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO(®) and OTEMTO(®) studies: a subgroup analysis by age. Int J Chron Obstruct Pulmon Dis. 2016 Oct 31;11:2701-2710. eCollection 2016. PubMed PMID: 27843306; PubMed Central PMCID: PMC5098524.

16: van Boven JF, Kocks JW, Postma MJ. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands. Int J Chron Obstruct Pulmon Dis. 2016 Sep 19;11:2191-2201. eCollection 2016. PubMed PMID: 27703341; PubMed Central PMCID: PMC5036592.

17: Halpin DM, Kerkhof M, Soriano JB, Mikkelsen H, Price DB. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir Res. 2016 Sep 23;17(1):120. PubMed PMID: 27663386; PubMed Central PMCID: PMC5034631.

18: Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies. Int J Chron Obstruct Pulmon Dis. 2016 Aug 29;11:2017-27. doi: 10.2147/COPD.S110389. eCollection 2016. PubMed PMID: 27621608; PubMed Central PMCID: PMC5010080.

19: Perriello EA, Sobieraj DM. The Respimat Soft Mist Inhaler, a Novel Inhaled Drug Delivery Device. Conn Med. 2016 Jun-Jul;80(6):359-64. Review. PubMed PMID: 27509644.

20: Selya-Hammer C, Gonzalez-Rojas Guix N, Baldwin M, Ternouth A, Miravitlles M, Rutten-van Mölken M, Goosens LM, Buyukkaramikli N, Acciai V. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Ther Adv Respir Dis. 2016 Oct;10(5):391-401. doi: 10.1177/1753465816657272. Epub 2016 Jul 12. PubMed PMID: 27405723.